Literature DB >> 28240601

FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging.

Hanjun Li, Pei Liu, Shuqin Xu, Yinghua Li, Joseph D Dekker, Baojie Li, Ying Fan, Zhenlin Zhang, Yang Hong, Gong Yang, Tingting Tang, Yongxin Ren, Haley O Tucker, Zhengju Yao, Xizhi Guo.   

Abstract

A hallmark of aged mesenchymal stem/progenitor cells (MSCs) in bone marrow is the pivot of differentiation potency from osteoblast to adipocyte coupled with a decrease in self-renewal capacity. However, how these cellular events are orchestrated in the aging progress is not fully understood. In this study, we have used molecular and genetic approaches to investigate the role of forkhead box P1 (FOXP1) in transcriptional control of MSC senescence. In bone marrow MSCs, FOXP1 expression levels declined with age in an inverse manner with those of the senescence marker p16INK4A. Conditional depletion of Foxp1 in bone marrow MSCs led to premature aging characteristics, including increased bone marrow adiposity, decreased bone mass, and impaired MSC self-renewal capacity in mice. At the molecular level, FOXP1 regulated cell-fate choice of MSCs through interactions with the CEBPβ/δ complex and recombination signal binding protein for immunoglobulin κ J region (RBPjκ), key modulators of adipogenesis and osteogenesis, respectively. Loss of p16INK4A in Foxp1-deficient MSCs partially rescued the defects in replication capacity and bone mass accrual. Promoter occupancy analyses revealed that FOXP1 directly represses transcription of p16INK4A. These results indicate that FOXP1 attenuates MSC senescence by orchestrating their cell-fate switch while maintaining their replicative capacity in a dose- and age-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28240601      PMCID: PMC5373872          DOI: 10.1172/JCI89511

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  73 in total

1.  The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p.

Authors:  A H Banham; N Beasley; E Campo; P L Fernandez; C Fidler; K Gatter; M Jones; D Y Mason; J E Prime; P Trougouboff; K Wood; J L Cordell
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

Review 2.  Osteoblasts in osteoporosis: past, emerging, and future anabolic targets.

Authors:  Pierre J Marie; Moustapha Kassem
Journal:  Eur J Endocrinol       Date:  2011-05-04       Impact factor: 6.664

Review 3.  Adipocyte differentiation: a transcriptional regulatory cascade.

Authors:  R P Brun; J B Kim; E Hu; S Altiok; B M Spiegelman
Journal:  Curr Opin Cell Biol       Date:  1996-12       Impact factor: 8.382

4.  Chiari I malformation, delayed gross motor skills, severe speech delay, and epileptiform discharges in a child with FOXP1 haploinsufficiency.

Authors:  Christopher W Carr; Daniel Moreno-De-Luca; Colette Parker; Holly H Zimmerman; Nikki Ledbetter; Christa Lese Martin; William B Dobyns; Omar A Abdul-Rahman
Journal:  Eur J Hum Genet       Date:  2010-06-23       Impact factor: 4.246

5.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

6.  p53 mutant mice that display early ageing-associated phenotypes.

Authors:  Stuart D Tyner; Sundaresan Venkatachalam; Jene Choi; Stephen Jones; Nader Ghebranious; Herbert Igelmann; Xiongbin Lu; Gabrielle Soron; Benjamin Cooper; Cory Brayton; Sang Hee Park; Timothy Thompson; Gerard Karsenty; Allan Bradley; Lawrence A Donehower
Journal:  Nature       Date:  2002-01-03       Impact factor: 49.962

7.  FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer.

Authors:  Takashi Shigekawa; Nobuhiro Ijichi; Kazuhiro Ikeda; Kuniko Horie-Inoue; Chikako Shimizu; Shigehira Saji; Kenjiro Aogi; Hitoshi Tsuda; Akihiko Osaki; Toshiaki Saeki; Satoshi Inoue
Journal:  Horm Cancer       Date:  2011-10       Impact factor: 3.869

8.  Rb regulates fate choice and lineage commitment in vivo.

Authors:  Eliezer Calo; Jose A Quintero-Estades; Paul S Danielian; Simona Nedelcu; Seth D Berman; Jacqueline A Lees
Journal:  Nature       Date:  2010-08-04       Impact factor: 49.962

9.  Osteoblast-targeted suppression of PPARγ increases osteogenesis through activation of mTOR signaling.

Authors:  Hongli Sun; Jin Koo Kim; Richard Mortensen; Lorraine P Mutyaba; Kurt D Hankenson; Paul H Krebsbach
Journal:  Stem Cells       Date:  2013-10       Impact factor: 6.277

10.  Wntless spatially regulates bone development through β-catenin-dependent and independent mechanisms.

Authors:  Zhendong A Zhong; Juraj Zahatnansky; John Snider; Emily Van Wieren; Cassandra R Diegel; Bart O Williams
Journal:  Dev Dyn       Date:  2015-08-21       Impact factor: 3.780

View more
  57 in total

Review 1.  Targeting Cell Senescence for the Treatment of Age-Related Bone Loss.

Authors:  Robert J Pignolo; Rebekah M Samsonraj; Susan F Law; Haitao Wang; Abhishek Chandra
Journal:  Curr Osteoporos Rep       Date:  2019-04       Impact factor: 5.096

2.  FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.

Authors:  Hanjun Li; Xiuguo Han; Shengbing Yang; Yongjie Wang; Yang Dong; Tingting Tang
Journal:  Oncogene       Date:  2021-03-14       Impact factor: 9.867

3.  The Long Non-coding RNA-ORLNC1 Regulates Bone Mass by Directing Mesenchymal Stem Cell Fate.

Authors:  Lei Yang; Yuan Li; Rui Gong; Manqi Gao; Chao Feng; Tianyi Liu; Yi Sun; Mengyu Jin; Dawei Wang; Ye Yuan; Gege Yan; Mingyu He; Elina Idiiatullina; Wenya Ma; Zhenbo Han; Lai Zhang; Qi Huang; Fengzhi Ding; Benzhi Cai; Fan Yang
Journal:  Mol Ther       Date:  2018-12-07       Impact factor: 11.454

Review 4.  Bone marrow mesenchymal stem cells: Aging and tissue engineering applications to enhance bone healing.

Authors:  Hang Lin; Jihee Sohn; He Shen; Mark T Langhans; Rocky S Tuan
Journal:  Biomaterials       Date:  2018-06-22       Impact factor: 12.479

5.  LncRNA RAD51-AS1 Regulates Human Bone Marrow Mesenchymal Stem Cells via Interaction with YBX1 to Ameliorate Osteoporosis.

Authors:  Beichen Li; Jing Wang; Fangrong Xu; Qinjue Wang; Quan Liu; Guantong Wang; Dengshun Miao; Qiang Sun
Journal:  Stem Cell Rev Rep       Date:  2022-06-21       Impact factor: 5.739

Review 6.  Senescent cells: an emerging target for diseases of ageing.

Authors:  Bennett G Childs; Martina Gluscevic; Darren J Baker; Remi-Martin Laberge; Dan Marquess; Jamie Dananberg; Jan M van Deursen
Journal:  Nat Rev Drug Discov       Date:  2017-07-21       Impact factor: 84.694

7.  Long noncoding RNA Bmncr regulates mesenchymal stem cell fate during skeletal aging.

Authors:  Chang-Jun Li; Ye Xiao; Mi Yang; Tian Su; Xi Sun; Qi Guo; Yan Huang; Xiang-Hang Luo
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

8.  Foxp2 regulates anatomical features that may be relevant for vocal behaviors and bipedal locomotion.

Authors:  Shuqin Xu; Pei Liu; Yuanxing Chen; Yi Chen; Wei Zhang; Haixia Zhao; Yiwei Cao; Fuhua Wang; Nana Jiang; Shifeng Lin; Baojie Li; Zhenlin Zhang; Zhanying Wei; Ying Fan; Yunyun Jin; Lin He; Rujiang Zhou; Joseph D Dekker; Haley O Tucker; Simon E Fisher; Zhengju Yao; Quansheng Liu; Xuechun Xia; Xizhi Guo
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-13       Impact factor: 11.205

9.  GATA6 regulates aging of human mesenchymal stem/stromal cells.

Authors:  Hongli Jiao; Brian E Walczak; Ming-Song Lee; Madeleine E Lemieux; Wan-Ju Li
Journal:  Stem Cells       Date:  2020-11-30       Impact factor: 6.277

10.  Regulation of osteogenesis via miR-101-3p in mesenchymal stem cells by human gingival fibroblasts.

Authors:  Eri Kaneda-Ikeda; Tomoyuki Iwata; Noriyoshi Mizuno; Takayoshi Nagahara; Mikihito Kajiya; Kazuhisa Ouhara; Minami Yoshioka; Shu Ishida; Hiroyuki Kawaguchi; Hidemi Kurihara
Journal:  J Bone Miner Metab       Date:  2020-01-23       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.